FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W54536727> ?p ?o ?g. }

• W54536727 endingPage "80" @default.
• W54536727 startingPage "169" @default.
• W54536727 abstract "In recent years, the prognosis of non-seminomatous germ-cell tumors has been greatly improved by the use of novel chemotherapeutic regimens including platinum derivatives. However, the prognosis remains poor for a certain proportion of these patients. We have therefore developed an intensive chemotherapy protocol (PEC) followed by bone marrow autografting: cisplatin (40 mg/m2/day x 5 d), etoposide (350 mg/m2/day x 5 d), cyclophosphamide (1,600 mg/m2/day x 4 d). Forty-four poor-prognosis patients were thus treated. The results can be stratified into 3 categories, as follows: I: 12 refractory patients: 3 CR, 6 PR, 2 failures, 1 unevaluable. Median survival was short (7 months, range 2-16 months); II: 6 patients with sensitive relapse: 5 CR, 1 unevaluable. Four patients remained in CR at 42, 45, 46 and 48 months; III: 26 patients who received PEC as consolidation therapy in the first CR-PR after courses of conventional chemotherapy and who were selected at the time of diagnosis on the basis of factors of poor prognosis: 16 CR, 3 PR, 7 unevaluable. Two-year disease-free survival (Kaplan-Meier) is 60%. The median duration of neutropenia (less than 0.5 x 10(9)/l) was 15 d (range 6-37) and that of thrombocytopenia (less than 20 x 10(9)/l), 13 d (range 3-32). The most significant non-hematologic toxicity was of the gastrointestinal tract; in particular severe mucositis. Four iatrogenic deaths occurred (2 candidiasis, 1 aspergillosis and 1 hemorrhage). Pharmacokinetic studies were used to determine the optimum time for reinfusing the marrow and provided information on the mechanism of the mucositis. In conclusion, PEC protocol showed a high efficacy with 94% response rate (68.5% CR) among the 35 evaluable pts. Patients refractory to conventional treatment did not appear to benefit from this intensive chemotherapy. However, it appears that it may be useful for patients with relapses sensitive to salvage therapy. Encouraging results were obtained with the PEC protocol administered as early consolidation for patients with identifiable risk factors at diagnosis. A multicenter, randomized trial is currently underway in France to compare this approach with standard conventional chemotherapy." @default.
• W54536727 created "2016-06-24" @default.
• W54536727 creator A5003804831 @default.
• W54536727 creator A5013215898 @default.
• W54536727 creator A5014184047 @default.
• W54536727 creator A5015114299 @default.
• W54536727 creator A5020762807 @default.
• W54536727 creator A5058301627 @default.
• W54536727 creator A5063017120 @default.
• W54536727 creator A5074429892 @default.
• W54536727 creator A5076189415 @default.
• W54536727 creator A5079724751 @default.
• W54536727 date "1990-01-01" @default.
• W54536727 modified "2023-09-27" @default.
• W54536727 title "[Value of high-dose chemotherapy followed by bone marrow autograft in non-seminomatous germinal tumor with poor prognosis. Results of the combination of cisplatinum, etoposide and cyclophosphamide (PEC protocol)]." @default.
• W54536727 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/2156588" @default.
• W54536727 hasPublicationYear "1990" @default.
• W54536727 type Work @default.
• W54536727 sameAs 54536727 @default.
• W54536727 citedByCount "1" @default.
• W54536727 crossrefType "journal-article" @default.
• W54536727 hasAuthorship W54536727A5003804831 @default.
• W54536727 hasAuthorship W54536727A5013215898 @default.
• W54536727 hasAuthorship W54536727A5014184047 @default.
• W54536727 hasAuthorship W54536727A5015114299 @default.
• W54536727 hasAuthorship W54536727A5020762807 @default.
• W54536727 hasAuthorship W54536727A5058301627 @default.
• W54536727 hasAuthorship W54536727A5063017120 @default.
• W54536727 hasAuthorship W54536727A5074429892 @default.
• W54536727 hasAuthorship W54536727A5076189415 @default.
• W54536727 hasAuthorship W54536727A5079724751 @default.
• W54536727 hasConcept C126322002 @default.
• W54536727 hasConcept C141071460 @default.
• W54536727 hasConcept C2776581026 @default.
• W54536727 hasConcept C2776694085 @default.
• W54536727 hasConcept C2776755627 @default.
• W54536727 hasConcept C2777063308 @default.
• W54536727 hasConcept C2778119113 @default.
• W54536727 hasConcept C2778496288 @default.
• W54536727 hasConcept C71924100 @default.
• W54536727 hasConcept C90924648 @default.
• W54536727 hasConceptScore W54536727C126322002 @default.
• W54536727 hasConceptScore W54536727C141071460 @default.
• W54536727 hasConceptScore W54536727C2776581026 @default.
• W54536727 hasConceptScore W54536727C2776694085 @default.
• W54536727 hasConceptScore W54536727C2776755627 @default.
• W54536727 hasConceptScore W54536727C2777063308 @default.
• W54536727 hasConceptScore W54536727C2778119113 @default.
• W54536727 hasConceptScore W54536727C2778496288 @default.
• W54536727 hasConceptScore W54536727C71924100 @default.
• W54536727 hasConceptScore W54536727C90924648 @default.
• W54536727 hasIssue "2" @default.
• W54536727 hasLocation W545367271 @default.
• W54536727 hasOpenAccess W54536727 @default.
• W54536727 hasPrimaryLocation W545367271 @default.
• W54536727 hasRelatedWork W2018507611 @default.
• W54536727 hasRelatedWork W2074454485 @default.
• W54536727 hasRelatedWork W2077567025 @default.
• W54536727 hasRelatedWork W2113231016 @default.
• W54536727 hasRelatedWork W2127123860 @default.
• W54536727 hasRelatedWork W2328789355 @default.
• W54536727 hasRelatedWork W2419350683 @default.
• W54536727 hasRelatedWork W2428528889 @default.
• W54536727 hasRelatedWork W2521216538 @default.
• W54536727 hasRelatedWork W3000675521 @default.
• W54536727 hasVolume "77" @default.
• W54536727 isParatext "false" @default.
• W54536727 isRetracted "false" @default.
• W54536727 magId "54536727" @default.
• W54536727 workType "article" @default.